Global inhibitory control in PD is impaired ON dopaminergic medication but not ON STN-DBS
Objective: The aim of our study is to obtain a better understanding of how DA and STN-DBS modulate basal ganglia (BG) pathway functions. Background: Patients…Effects of continuous apomorphine infusion on motor and nonmotor symptoms in Parkinson’s disease without cognitive deterioration
Objective: The aim of the present study was to investigate the influence of apomorphine pump in Parkinson’s disease (PD) on motor and nonmotor symptoms, including…Domain-Specific Cognitive Impairment in Non-Demented Parkinson’s Disease Psychosis
Objective: Our objective was to determine whether psychosis in non-demented Parkinson’s disease (PD) patients is associated with domain-specific cognitive impairment on the Mini-Mental State Exam…Grey matter abnormalities associated with early cognitive decline in Parkinson’s disease
Objective: To identify patterns of grey matter (GM) abnormalities in patients with Parkinson's disease (PD) with different cognitive profiles. Background: Cognitive symptoms occur already in…Subjective visual vertical in patients with early Parkinson’s disease
Objective: To identify the changes of subjective visual vertical and any correlation between SVV and cognitive/motoric dysfunctions in Parkinson's disease. Background: Dysfunction of sensory system is…Examining central cognitive processing speed as an early marker of Huntington’s disease (HD) onset
Objective: To examine central processing speed as an early marker of Huntington’s disease (HD) onset using the Computerized Test of Information Processing (CTiP). Background: The CTiP,…Cognitive and demographic predictors of progression to MCI and dementia in Parkinson’s disease
Objective: To determine the association between demographic and cognitive features and subsequent progression of cognitive symptoms in Parkinson’s disease (PD). Background: Most patients diagnosed with…Cognitive data in the Parkinson’s Progression Markers Initiative: Comparison of normative data approaches
Objective: It is important to understand underlying psychometric properties of the cognitive tests included in the Parkinson’s Progression Markers Initiative (PPMI) dataset to interpret the…The clinical profile associated to Amyloid-beta 42 and Tau cerebrospinal fluid levels in non-demented PD patients
Objective: To define cerebrospinal fluid (CSF) levels of Amyloid-beta 1-42 (Aß1-42-), total (h-) and phosphorylated (p-)Tau in a large cohort of non-demented Parkinson’s disease (PD)…Oscillatory dynamics of impaired novelty detection at early Parkinson’s disease
Objective: In this work we aimed to describe the brain oscillations associated with impaired novelty detection at early PD. Background: Cognitive impairment, especially attentional and…
- « Previous Page
- 1
- …
- 99
- 100
- 101
- 102
- 103
- …
- 128
- Next Page »